Göttingen Graduate Center for Neurosciences, Biophysics, and Molecular Biosciences

Singh, Shiv K., Ph.D.


  • 2006–2010: Ph.D. in Molecular Medicine, Philipps University Marburg, Germany
  • 2011–2013: Postdoctoral Fellow, Philipps University Marburg, Germany
  • 2014–2016: Postdoctoral Fellow, Barrow Neurological Institute, Phoenix, AZ, USA
  • 2016–2018: Junior Group Leader, Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Germany
  • Since 2018: Max-Eder Group Leader, Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Germany
  • Since 2025: Mildred-Scheel Professor and Chair of Targeting Tumor Heterogeneity, Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Germany



Major Research Interests


  • Exploration of cross-talk between inflammatory immune components and tumor cells in pancreatic cancer progression and chemoresistance
  • Identification of lineage-specific transcription factors and chromatin modifiers as potential biomarker for the patient stratification in pancreatic cancer
  • Establishment of epigenetic-based therapies for precision treatment in pancreatic cancer



Homepage Department/Research Group

https://gastroenterologie.umg.eu/forschung/working-groups/working-group-singh/



Selected Recent Publications


  • Urbach L, Wieland L, Penz F, Samuel RD, Küffer S, Klein L, Lenz C, Sax U, Ghadimi M, Schulz-Heddergott R, Hessmann E, Ellenrieder V, Dusetti N, Singh SK (2025). TP53 missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer. Science Advances, 11(27):2339.

  • Klein L, Tu M, Krebs N, Urbach L, Grimm G, Umair L, Penz F, Blandau A, Xueyan Wu, Samuel RD, Küffer S, Wegwitz F, Chan N, Aliar K, Vyas F, Kishore U, Hessmann E, Trumpp A, Espinet E, Papantonis A, Khokha R, Ellenrieder V, Grünwald BT, Singh SK (2025). Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer. Nature Communications, 16(1):335

  • Espinet E, Klein L, Puré E, Singh SK (2022). Mechanisms of PDAC subtype heterogeneity and therapy response.
    Trends in Cancer; 12:1060-1071.

  • Krebs N, Klein L, Wegwitz F, Espinet E, Maurer C, Tu M, Xu X, Küffer S, Bohnenberger H, Cameron S, Bruner M, Neesse A, Kishore U, Hessmann E, Trumpp A, Ströbel P, Brekken R, Ellenrieder V, Singh SK* (2022). Axon Guidance Receptor ROBO3 Modulates Subtype Identity and Prognosis via AXL-associated Inflammatory Network in Pancreatic Cancer. JCI Insight; 16:e154475

  • Tu M, Klein L, Espinet E, Georgomanolis T, Wegwitz F, Xiaojuan L, Urbach L, Danieli-Mackay A, Küffer S, Bojarczuk K, Mizi A, Günesdogan U, Chapuy B, Gu Z, Kishore U, Neesse A, Ströbel P, Hessmann E, Hahn SA, Trumpp A, Papantonis A, Ellenrieder V, Singh SK (2021). TNFα-producing Macrophages Determine Subtype Identity and Prognosis via AP1 Enhancer Reprogramming in Pancreatic Cancer. Nature Cancer; 2:1185-1203.